Commercial Printing

Deluxe

Deluxe released FY2026 Q1 earnings on May 6 Pre-Market EST, actual revenue USD 538.1 M (forecast USD 534.97 M), actual EPS USD 0.7732 (forecast USD 0.57)

Deluxe Reports Q1 Earnings Per Share of $0.77

Deluxe to release FY2026 Q1 earnings on May 6 Pre-Market EST, forecast revenue USD 534.97 M, EPS USD 0.57

Deluxe released FY2025 Q4 earnings on January 28 After-Market EST, actual revenue USD 535.22 M (forecast USD 517.4 M), actual EPS USD 0.2601 (forecast USD 0.495)

Deluxe released FY2025 Annual Earnings on January 28 After-Market (EST), Actual Revenue: USD 2.133 B (Forecast: USD 2.115 B), Actual EPS: USD 1.8 (Forecast: USD 2.03)

Deluxe to Release FY2025 Earnings on January 28 After-Market EST, Forecast Revenue USD 2.115 B, EPS USD 2.03

Deluxe and Visa Partner to Launch dlxFastFundsSM

Deluxe released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 540.2 M (forecast USD 526.5 M), actual EPS USD 0.739 (forecast USD 0.465)

Deluxe released FY2025 9 Months earnings on November 5 After-Market (EST), actual revenue USD 1.598 B, actual EPS USD 1.546

Deluxe to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 526.5 M, EPS USD 0.465

Deluxe released FY2025 Semi-Annual Earnings on August 6 After-Market EST, with actual revenue of USD 1.058 B and EPS of USD 0.8066

Deluxe released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 521.3 M (forecast USD 526.93 M), actual EPS USD 0.4955 (forecast USD 0.35)

Deluxe to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 526.93 M, EPS USD 0.35

Deluxe Corporation Releases Q2 2025 Earnings Report

Deluxe Corporation CFO Purchases Company Stock

Squarepoint and Smartleaf Adjust Their Holdings in Deluxe

Deluxe Corporation Partners with MyKidReports to Optimize Payment Solutions

Square 9 Softworks and Deluxe Form Strategic Partnership

Aquatic Capital Management Reduces Holdings in Deluxe Co.

TD Securities Downgrades Deluxe Rating and Target Price

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

IDGT

XDAT

SRVR

CLOU

DTCR

Deluxe (DLX) has announced a merchant services partnership with Dollar Bank, enhancing its cloud-based payment infrastructure. Despite recent stock struggles, with a 12.87% drop over the past week, long-term shareholders have seen returns of 54.25% over the past year. Currently trading at $23.16, Deluxe is considered undervalued compared to a fair value of $32.67, raising questions about future growth potential amidst declining print revenue.

Simplywall

iShares US Digital Infrastructure and Real Estate ETF

Franklin Exponential Data ETF

Pacer Data & Infrastructure Real Estate ETF

Global X Cloud Computing ETF

Global X Data Center & Dgtl Infrs ETF

Proshares Big Data Refiners ETF

Assessing Deluxe (DLX) Valuation As New Dollar Bank Partnership Draws Attention

Deluxe to Power Payment Solutions for Dollar Bank's Business Customers | DLX Stock News

StockTitan

Deluxe to Power Payment Solutions for Dollar Bank's Business Customers | DLX Stock News

Deluxe Corporation (NYSE:DLX) reported quarterly results with revenues of $538 million and a profit of $0.77 per share, exceeding analyst expectations. Despite a 14% drop in stock price, analysts have adjusted their 2026 revenue forecast to $2.06 billion, reflecting a 3.5% decline, while EPS estimates remain at $2.83. The consensus price target increased by 6.5% to $32.67, indicating stable sentiment despite lower revenue projections. Deluxe is expected to lag behind industry growth, with a forecasted annual revenue decline of 4.7% compared to a 5.9% growth for peers.

Deluxe Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Earnings Watch

Deluxe | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 538.1 M

Deluxe (DLX) reported Q1 revenue of $538.1 million and EPS of $0.77, with trailing 12-month figures showing revenue of $2.1 billion and EPS of $2.31, reflecting 85.5% earnings growth. The company’s net profit margin improved to 4.9% from 2.6% last year. Despite a P/E ratio of 11.4x, significantly below industry averages, analysts have a consensus price target of $32.67, indicating potential upside. However, concerns about weak interest coverage and debt servicing may impact dividend sustainability, creating a tension between bullish and bearish perspectives on the stock's future performance.

Deluxe (DLX) Q1 Margins And EPS Growth Challenge Bearish Flat Profitability Narrative

Deluxe Corp. reported a successful Q1 earnings call, highlighting a profitable transition with a 19.7% increase in adjusted EBITDA to $117.9 million and a 45% rise in adjusted diluted EPS to $1.05. Payments and Data segments now account for 51% of total revenue, reflecting a strategic pivot. Despite a 5.9% decline in print revenue, overall revenue grew modestly by 0.3%. The company achieved a net debt reduction to $1.37 billion and maintained strong free cash flow of $27.3 million. Management anticipates moderation in Data Solutions growth in the latter half of the year.

Tip Ranks

Washington Trust Bancorp

Deluxe Corp. Earnings Call Highlights Profitable Shift

BCRX

BioCryst Pharma (NASDAQ:BCRX) reported Q1 2026 net revenue of $148.3 million, meeting expectations, with strong new patient prescriptions. Despite a manufacturing issue affecting the pediatric formulation of Orladeo, the company maintains its 2026 revenue guidance of $625-$645 million. The development of Nevenibart is progressing well, with the Phase 3 Alpha Orbit trial nearing completion. The acquisition of Astria Therapeutics is ahead of schedule, contributing to a 17% year-on-year revenue increase. BioCryst remains focused on expanding its market presence and addressing pediatric needs in HAE prophylaxis.

benzinga_article

BioCryst Pharma

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VG Health

iShares Global Healthcare

iShares US Pharma

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Astria Therapeutics

Full Transcript: BioCryst Pharma Q1 2026 Earnings Call

Deluxe shares are trading lower after the company issued its FY2026 adjusted EPS and FY2026 sales guidance below estimates.

Deluxe(DLX.US)

Assessing Deluxe (DLX) Valuation As New Dollar Bank Partnership Draws Attention

Deluxe to Power Payment Solutions for Dollar Bank's Business Customers | DLX Stock News

Deluxe Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Deluxe | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 538.1 M

Deluxe (DLX) Q1 Margins And EPS Growth Challenge Bearish Flat Profitability Narrative

Deluxe Corp. Earnings Call Highlights Profitable Shift

Full Transcript: BioCryst Pharma Q1 2026 Earnings Call

Deluxe shares are trading lower after the company issued its FY2026 adjusted EPS and FY2026 sales guidance below estimates.